Pipeline

Yap-Tead

Inventiva’s is actively working on the newly discovered signaling pathway Hippo Pathway which has been shown to be involved in controlling cell proliferation and organ size. Our program seeks at identifying small molecules that bind to the Hippo downstream transcription factor TEAD and thus preventing its association with Yap and the activation of oncogenic pathways. 

YAP-TEAD inhibitors represent a promising and innovative therapeutic strategy to address unmet medical needs:

English

IVA336

Targeted Disease

MPS I, MPS II et MPS VI

Mucopolysaccharidoses (MPS) are a group of rare genetic disorders characterized by deficiency of lysosomal enzymes responsible for the normal degradation of glycosaminoglycans (GAGs) or mucopolysaccharides.
English

IVA337

Targeted Diseases

Non-alcoholic Steato-hepatitis (NASH)

Non-alcoholic steato-hepatitis (NASH),a severe and chronic form of non-alcoholic fatty liver disease has become a leading contributor to the need for liver transplantation. NASH increases 5 to 10 fold the risk of liver related mortality and is expected to become the leading cause of liver transplantation by 2020.

English